OCIL/CLEC2d Antibody [Alexa Fluor® 350]

• Reactivity: Hu
• Applications: WB, Flow, CyTOF-ready
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Alexa Fluor 350

OCIL/CLEC2d Antibody [Alexa Fluor® 350] Summary

• Immunogen: E. coli-derived recombinant human OCIL/CLEC2d
  Ser57-Val191
  Accession # Q9UHP7
• Specificity: Detects human OCIL/CLEC2d in direct ELISAs and Western blots. In direct ELISAs, less than 10% cross-reactivity with recombinant mouse (rm) OCIL is observed and less than 1% cross-reactivity with recombinant human (rh) CLEC2B, and rhCLEC2A i
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • CyTOF-ready
  • Flow Cytometry
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for OCIL/CLEC2d Antibody [Alexa Fluor® 350]

• CLAXLLT-1
• CLEC2D
• C-type lectin domain family 2 member D
• C-type lectin domain family 2, member D
• C-type lectin related f
• Lectin-like NK cell receptor
• Lectin-like transcript 1
• LLT1
• LLT1Osteoclast inhibitory lectin
• OCIL
• OCILmember D

Background

Human OCIL/CLEC2d, also known as Lectin-Like Transcript-1 (LLT-1), is a type II transmembrane protein belonging to the natural killer (NK) cell receptor group of the C-type lectin superfamily. It is found on hematopoietic cells, osteoblasts, and chondrocytes. By alternative splicing, at least three isoforms exist. Isoform 1 is synthesized as a 191 amino acid (aa) precursor with a C-terminal 132 aa extracellular domain (ECD) that contains the C-type lectin domain. The aa sequence of human OCIL isoform 1 ECD is 49% and 50% identical to the mouse and rat OCIL ECD, respectively. Human OCIL preferentially binds high molecular weight sulfated glycosaminoglycans and is a ligand for the single human NKR-P1A receptor (CD161). Human OCIL blocks osteoclast differentiation. Engagement of OCIL with CD161 on NK cells also inhibits NK cell-mediated cytotoxicity and IFN-gamma secretion.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.